Showing 1 - 10 of 10 Maen Abdelrahim
M3541 in Combination With Radiotherapy in Subjects With Solid Tumors

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Ashley Towne

Phone: 346.238.2006

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in subjects with solid tumors with ma ... Read more >

A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This is an open-label, phase 2 comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients with advanced pancreatic adenocarcinoma who have not received pri ... Read more >

A Study of Zolbetuximab Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. < ... Read more >

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Prystash

Phone: 713.441.6564

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

CDX-1140 : A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Prystash

Phone: 713.441.6564

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in ... Read more >

N1048 Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. ... Read more >

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pan ... Read more >

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Prystash

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available